Edge Therapeutics Announces First Patient Treated in Phase 3 NEWTON 2 Study of EG-1962 in Adult Patients with Aneurysmal Subarachnoid Hemorrhage Pivotal, double-blind, placebo-controlled global study will compare EG-1962 to standard of care oral nimodipine BERKELEY...
Edge Therapeutics Announces Appointment of Harry J. Sacks, M.D., FAAP, as Vice President, Clinical Development BERKELEY HEIGHTS, N.J., July 06, 2016 (GLOBE NEWSWIRE) — Edge Therapeutics, Inc. (Nasdaq:EDGE), a clinical-stage biotechnology company developing novel...
CardioKinetix Announces the 500th Parachute Heart Failure Device Implantation July 21, 2016 Menlo Park, Calif. – July 21, 2016— CardioKinetix Inc., a medical device company pioneering a catheter-based treatment for heart failure, today announced that 500 patients have...
Bio-Techne Announces Agreement to Acquire Advanceed Cell Diagnostics July 06, 2016 Minneapolis/July 6, 2016/–Bio-Techne Corporation (NASDAQ: TECH) announced today that it has agreed to acquire Advanced Cell Diagnostics (ACD) for $250 million in cash plus...
CRISPR Therapeutics Raises Additional $38M as Part of Series B Financing Funding to Support the Development of its CRISPR/Cas9 Gene-Editing Platform and Programs BASEL, Switzerland and Cambridge, Massachusetts – CRISPR Therapeutics, a biopharmaceutical company focused...
Unum Therapeutics Announces Active Investigational New Drug (IND) Application for ACTR087 in Patients with Relapsed/Refractory B-cell Lymphoma Company Focused on Initiating Multi-center, Phase 1 Trial in Second Half of 2016 – CAMBRIDGE, MA, June 20, 2016 – a...
Recent Comments